PHM Stock Analysis: Pharma Mar S.A. | MC
Biotechnology | MC, Spain | Market Cap: 1.366m EUR | 12M Return: 21.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.89M
Qual. Beats: 0
Rev. Trend: 76.2%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Pharma Mar, S.A. (PHM) is a Madrid-based biopharmaceutical company founded in 1986 that focuses on discovering, developing, and commercializing bio-active compounds for oncology. It operates through two segments: Oncology and RNA Interference (gene-silencing therapeutics), with commercial activity spanning Europe, the United States, and other international markets.
The companys marketed portfolio includes Yondelis (derived from the sea squirt Ecteinascidia turbinata, approved for soft tissue sarcoma and ovarian cancer), Zepzelca (a synthetic agent for small cell lung cancer), and Aplidin (extracted from the ascidian Aplidium albicans, indicated for multiple myeloma). Pharma Mars development pipeline includes LAGOON and SaLuDo in Phase III trials, PM534 and PM54 in Phase I for solid tumors, and SYL1801 in Phase II for ophthalmologic conditions such as age-related macular degeneration.
As a small-cap biotechnology firm, Pharma Mar follows a high-risk, R&D-intensive business model typical of the biopharma sector, where revenue depends on a limited number of approved oncology products and long product development cycles subject to regulatory approval. The company is also notable for its specialization in marine-derived pharmaceuticals, a niche area of natural-product drug discovery, and complements its oncology work with RNA interference-based research aimed at silencing disease-related gene expression.
- Zepzelca US sales growth drives oncology revenue
- LAGOON Phase III readout in small cell lung cancer
- Yondelis faces competition in soft tissue sarcoma market
| Net Income: 80.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 20.48 > 1.0 |
| NWC/Revenue: 81.72% < 20% (prev 89.06%; Δ -7.34% < -1%) |
| CFO/TA 0.18 > 3% & CFO 68.0m > Net Income 80.5m |
| Net Debt (-117.5m) to EBITDA (69.2m): -1.70 < 3 |
| Current Ratio: 3.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (17.2m) vs 12m ago -0.54% < -2% |
| Gross Margin: 92.66% > 18% (prev 94.41%; Δ -1.76% > 0.5%) |
| Asset Turnover: 62.73% > 50% (prev 52.70%; Δ 10.03% > 0%) |
| Interest Coverage Ratio: 24.85 > 6 (EBIT TTM 61.1m / Interest Expense TTM 2.46m) |
| A: 0.48 (Total Current Assets 273.5m - Total Current Liabilities 89.2m) / Total Assets 385.3m |
| B: 0.61 (Retained Earnings 235.4m / Total Assets 385.3m) |
| C: 0.17 (EBIT TTM 61.1m / Avg Total Assets 359.4m) |
| D: 1.84 (Book Value of Equity 249.7m / Total Liabilities 135.6m) |
| Altman-Z'' = 8.21 = AAA |
| DSRI: 0.85 (Receivables 40.0m/36.8m, Revenue 225.4m/175.7m) |
| GMI: 1.02 (GM 94.41% / 92.66%) |
| AQI: 1.15 (AQ_t 0.14 / AQ_t-1 0.12) |
| SGI: 1.28 (Revenue 225.4m / 175.7m) |
| TATA: 0.03 (NI 80.5m - CFO 68.0m) / TA 385.3m) |
| Beneish M = -2.84 (Cap -4..+1) = A |
As of July 08, 2026, the stock is trading at EUR 82.90 with a total of 83,107 shares traded. Over the past week, the price has changed by -5.81%, over one month by +10.61%, over three months by +13.13% and over the past year by +21.10%.
Current recommended Stop Loss: 74.60 (which is 10% or 2.5 ATR below the current price).
Pharma Mar S.A. has no consensus analysts rating.
P/E Trailing = 17.1258
P/E Forward = 54.0541
P/S = 6.0262
P/B = 5.2575
P/EG = 0.3119
Revenue TTM = 225.4m EUR
EBIT TTM = 61.1m EUR
EBITDA TTM = 69.2m EUR
Long Term Debt = 33.2m EUR (from longTermDebt, last quarter)
Short Term Debt = 13.1m EUR (from shortTermDebt, last quarter)
Debt = 50.4m EUR (from shortLongTermDebtTotal, last quarter) + Leases 2.85m
Net Debt = -117.5m EUR (calculated: Debt 50.4m - CCE 167.9m)
Enterprise Value = 1.25b EUR (1.37b + Debt 50.4m - CCE 167.9m)
Interest Coverage Ratio = 24.85 (Ebit TTM 61.1m / Interest Expense TTM 2.46m)
EV/FCF = 21.62x (Enterprise Value 1.25b / FCF TTM 57.8m)
FCF Yield = 4.63% (FCF TTM 57.8m / Enterprise Value 1.25b)
FCF Margin = 25.63% (FCF TTM 57.8m / Revenue TTM 225.4m)
Net Margin = 35.70% (Net Income TTM 80.5m / Revenue TTM 225.4m)
Gross Margin = 92.66% ((Revenue TTM 225.4m - Cost of Revenue TTM 16.6m) / Revenue TTM)
Gross Margin QoQ = 91.47% (prev 93.59%)
Tobins Q-Ratio = 3.24 (Enterprise Value 1.25b / Total Assets 385.3m)
Interest Expense / Debt = 4.88% (Interest Expense 2.46m / Debt 50.4m)
Taxrate = 4.07% (65.0k / 1.60m)
NOPAT = 58.6m (EBIT 61.1m * (1 - 4.07%))
Current Ratio = 3.06 (Total Current Assets 273.5m / Total Current Liabilities 89.2m)
Debt / Equity = 0.20 (Debt 50.4m / totalStockholderEquity, last quarter 249.7m)
Debt / EBITDA = -1.70 (Net Debt -117.5m / EBITDA 69.2m)
Debt / FCF = -2.03 (Net Debt -117.5m / FCF TTM 57.8m)
Total Stockholder Equity = 225.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 22.39% (Net Income 80.5m / Total Assets 385.3m)
RoE = 35.74% (Net Income TTM 80.5m / Total Stockholder Equity 225.1m)
RoCE = 23.66% (EBIT 61.1m / Capital Employed (Equity 225.1m + L.T.Debt 33.2m))
RoIC = 19.68% (NOPAT 58.6m / Invested Capital 297.8m)
WACC = 7.54% (E(1.37b)/V(1.42b) * Re(7.65%) + D(50.4m)/V(1.42b) * Rd(4.88%) * (1-Tc(0.04)))
Discount Rate = 7.65% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -62.87 | Cagr: -1.09%
[DCF] Terminal Value 75.44% ; FCFF base≈57.8m ; Y1≈58.0m ; Y5≈61.5m
[DCF] Fair Price = 62.02 (EV 955.8m - Net Debt -117.5m = Equity 1.07b / Shares 17.3m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.07 | # QB: 0
Revenue Correlation: 76.21 | Revenue CAGR: 10.32% | SUE: -0.03 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.18 | Chg30d=-39.48% | Revisions=-25% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.20 | Chg30d=-49.38% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=2.32 | Chg30d=-28.80% | Revisions=+25% | GrowthEPS=-46.1% | GrowthRev=-4.9%
EPS next Year (2027-12-31): EPS=6.15 | Chg30d=-16.64% | Revisions=+25% | GrowthEPS=+165.7% | GrowthRev=+41.4%
[Analyst] Revisions Ratio: +17% (up=2, down=1)